Skip to main content

fanapt

Generic: iloperidone

fanapt: developed by 1 company · 1 FDA decision.

fanapt evidence translation

What we can confirm

What it means

Source-backed records connect fanapt to VNDA; that link alone does not prove the drug works.

What to watch

Watch for new trials or company disclosures after the FDA record.
BioSniper AIPage evidence connected

Prepared research question

How could fanapt → VNDA affect its developer, and what evidence supports the link?

Run cited research

Traceable citations · Unknowns marked

Development Pipeline (1)
CompanyPhase
Vanda Pharmaceuticals Inc. (VNDA)Approved
FDA Decisions1 records
Approval1 INDICATIONS AND USAGE FANAPT ® is indicated for: Treatment of schizophrenia in adults [see Clinical Studies (14.1) ]. Acute treatment of manic or mixed episodes associated with bipolar I disorder in adults [see Clinical Studies (14.2) ] . FANAPT is an atypical antipsychotic indicated for: Treatment of schizophrenia in adults. ( 1 , 14.1 ) Acute treatment of manic or mixed episodes associated with bipolar I disorder in adults. ( 1 , 14.2 )(VNDA)FDA ↗
NDA022192Type 1 - New Molecular EntityStandardOralTablet

Frequently asked questions

Who is developing fanapt?

fanapt is being developed by Vanda Pharmaceuticals Inc..

What is fanapt's latest FDA decision?

The most recent tracked FDA decision for fanapt is Approval for 1 INDICATIONS AND USAGE FANAPT ® is indicated for: Treatment of schizophrenia in adults [see Clinical Studies (14.1) ]. Acute treatment of manic or mixed episodes associated with bipolar I disorder in adults [see Clinical Studies (14.2) ] . FANAPT is an atypical antipsychotic indicated for: Treatment of schizophrenia in adults. ( 1 , 14.1 ) Acute treatment of manic or mixed episodes associated with bipolar I disorder in adults. ( 1 , 14.2 ), dated May 6, 2009.